Fosun Pharma (02196) has issued an announcement that its controlling subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., has launched a Phase III clinical trial in China for FXS6837 capsules (formerly known as project code XH-S003) for the treatment of paroxysmal nocturnal hemoglobinuria.

The announcement was released by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196), the listed entity FOSUN PHARMA, confirming that Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196) is the parent group company involved in this development. The trial marks a significant step in the clinical development of FXS6837 for this rare blood disorder.

The Phase III trial is the final stage of clinical testing before a drug can be submitted for regulatory approval, and its initiation indicates that FXS6837 has advanced through earlier phases of safety and efficacy evaluation. Paroxysmal nocturnal hemoglobinuria is a rare, acquired, life-threatening blood disease characterized by the destruction of red blood cells, blood clots, and bone marrow failure.

The controlling subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., is responsible for the clinical development of FXS6837. The trial's commencement in China represents progress in the company's pipeline for hematology treatments. Further details regarding the trial design, endpoints, or timelines were not disclosed in the announcement.